Canaccord analyst Whitney Ijem lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $18 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report was straightforward, with the more notable news coming earlier in December with the announcement of positive clinical data from cohort 1 of TN-201’s Ph1b/2 (MyPeak-1) for the treatment of MYBPC3-associated HCM.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Buy Rating for Tenaya Therapeutics: Strong Clinical Progress and Financial Stability
- Biotech Alert: Searches spiking for these stocks today
- Tenaya Therapeutics price target lowered to $5 from $15 at Morgan Stanley
- Tenaya Therapeutics Advances Gene Therapy Pipeline
- Tenaya Therapeutics price target lowered to $9 from $18 at Chardan